EFFECT OF ALENDRONATE COMBINED WITH ALFACALCIDOL ON THE BIOLOGICAL STABILITY OF HIP JOINT ENDOPROSTHESIS IN PATIENTS WITH SYSTEMIC OSTEOPOROSIS
https://doi.org/10.14341/osteo2013124-28
Abstract
In a comparative study we investigated the influence of a combination of alendronate and alfacalcidol on the dynamics of bone mass density (BMD) at the site attached to the femoral component of endoprosthesis in total hip replacement in patients with systemic osteoporosis. Evaluation of performance of pharmacotherapy in the postoperative period on osteoporosis, systemic osteoporosis, sustained BMD deficit at Gruen regions confirmed that the essential component of osteointegration at the «implant-bone» site during the period of physiological adaptive remodeling after arthroplasty in women suffering from systemic osteoporosis is the pharmacological correction of the intensity of bone resorption in post-operative period.
References
1. Клюшниченко И.В.Независимые от имплантата факторы риска развития асептической нестабильности эндопротезов тазобедренного сустава. Автореферат дис. к.м.н. 2008. 34 С.
2. Миронов С.П., Родионова С.С. Остеопороз как одна из проблем травматологии и ортопедии. Сборник тезисов конференции «Проблема остеопороза в травматологии и ортопедии 2000, с.2
3. Родионова С.С. Метаболические остеопатии, системный остеопороз и остеомаляция у взрослых. Автореф. докт. дисс. 1992. 27 С.
4. Родионова С.С., Нуждин В.И., Морозов А.К., клюшниченко И.В. Остеопороз как фактор риска асептической нестабильности при эндопротезировании тазобедренного сустава. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2007, №2 апрель-июнь, с.35-40.
5. Arabmotlagh M., Rittmeister M., Hennigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J. Orthop. Res. 2006, Jul. 24(7):1336-41.
6. Bragdon C. R., Doherty A.M., Jasty M., Rubash H., Harris W. H. Effect of oral alendronate on net bone ingrowth into canine cementless total hips. J Arthroplasty. 2005, Feb.20(2).258-63.
7. Chapurlat R. D., Arlot M., Burt-Pichat B., Chavassieux P., Roux J. P et.al Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res. 2008, vol. 23(7), p. 1150-1; author reply p. 1152-3.
8. Cranney А., Wells G.,,Willan A.,, Griffith L., Zytaruk N., Robinson V., Black D., Adachi J., Shea B.,,Tugwell P., Guyatt G. The osteoporosis methodology group and the osteoporosis research advisory group. 2002. «Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women: Ten Years Experience with Alendronate for Osteoporosis in Postmenopausal Women». Endocrine Reviews.2002, 23(4):508-516.
9. Follet H., Li J., Phipps R.J., Hui S., 8. Condon K., Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone. 2007,vol.40(4), p. 1172-7.
10. Glassman A.H., Bobyn J.D., Tanzer M. New femoral designs: do they influence stress shielding? Clin Orthop Relat Res. 2006, № 453, p. 64-74.
11. Gruen T.A. Radiographic criteria for the clinical performance of uncemented total joint replacements. Quantitative characterization and performance of porous implants for hard tissue applications. ASTM STP 953, Philadelphia, American Society for testing material, 1987, 207-218.
12. Karrholm J, Borssen B, Lowenhielm G, Snorrason F. Does early micromotion of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up of 84 cemented prostheses. J Bone Joint Surg Br. 1994;76:912-917.
13. Korovessis P,Droutsas V., Piperos G., Michael A. et Course of bone mineral density changes around cementless Zweymuller total hip arthroplasty. A 4-year follow-up study. Arch. Orthop. Trauma Surg 1997. p.116, 60-65.
14. Lai K., Shen W., Yang C. et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. J. Bone J. Surg. 2005.Vol. 87A. P. 2155-2159.
15. Lilian I., Plotkin I., Virginia Lezcano,3 Jeff Thostenson,4 Robert S Weinstein,1 Stavros C Manolagas,1 and Teresita Bellido, Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In Vivo. J Bone Miner Res. 2008 -vol.23(11) p. 1712-1721.
16. McMcAuley JP, Sychterz CJ, Engh CA Sr. Influence of porous coating level on proximal femoral remodeling. A postmortem analysis. Clin Orthop Relat Res. 2000 Feb;(371):146-53.
17. Nehme A., Maalouf G., Tricoire J.L., Giordano G., Chiron P., Puget J. Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study. Rev. Chir. Orthop. Rep. App. Moteur.2003. 89.p.593-598.
18. Randle R., Hungerford M., Materna W. et al. Higher failure rate and stem migration of an uncemented femoral component in patients with femoral head osteonecrosis than in patients with osteoarthrosis. Acta Orthop. Scand.2005. Vol. 76, N 1. P. 49-55.
19. Rosenthall L., Bobyn J., Brooks C. Temporal changes of periprosthetic bone density in patients with a modular noncemented femoral prosthesis. J Arthroplasty 1999, 14 71-76.
20. Rubash H,Dorr L,Jacobs J, Maloney, W., Saag, K., Malbecq, W., Leung, A. et. al. Does alendronate inhibit the progressions of periprosthetic osteolysis? Trans. ORS 2004. 29:1492.
21. Shanbhag A.S., Hasselman C.T., Rubash H.E. The John Charnley Award :ingibition of wear debris mediated osteolysis in a canine total hip arthrophlasty modyl. Clin Orthop.1997. №344, p. 33-43.
22. Stephen Meraw S., Reeve С.М. Qualitative analysis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J. Periodontol, 1999,V. 70. №10. Р 1228-1233.
23. Wang C. J.,Wang J. W., Ko J.V., Weng L. H., Huang C. C. Thee-yars changes in bone mineral density around the knee after a six -month course of oral altendronate following total knee arthroplasty:a prospective randomized study. J. Bone Joint Surg (Am.)2006., 88, р.267-272.
24. Wilkinson JM, Stockley I, Peel NF, et al. Effect of pamidronate in preventing local bone loss after total hip arthroplasty: a randomized, double-blind, controlled trial.J.Bone Miner Res 2001; 16(3):556-564.
Review
For citations:
Rodionova S.S., Turgumbayev T.N. EFFECT OF ALENDRONATE COMBINED WITH ALFACALCIDOL ON THE BIOLOGICAL STABILITY OF HIP JOINT ENDOPROSTHESIS IN PATIENTS WITH SYSTEMIC OSTEOPOROSIS. Osteoporosis and Bone Diseases. 2013;16(1):24-28. (In Russ.) https://doi.org/10.14341/osteo2013124-28
Views:
414
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
